Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000907654-25-000017
Filing Date
2025-12-11
Accepted
2025-12-11 16:32:48
Documents
2
Period of Report
2025-12-11

Document Format Files

Seq Description Document Type Size
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.html 3  
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.xml 3 1502
2 POWER OF ATTORNEY exhibit24.txt EX-24 5968
  Complete submission text file 0000907654-25-000017.txt   9255
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Issuer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O EDGEWISE THERAPEUTICS, INC. 1715 38TH STREET BOULDER CO 80301
Business Address
Martin Christopher Nathan (Reporting) CIK: 0002097992 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-22873 | Film No.: 251565446